PROFILE: Chi-Med Lays Out Broad Strategy As Fruquintinib Advances
This article was originally published in PharmAsia News
Newly NASDAQ-listed Chi-Med has completed enrollment in a Phase III trial with fruquintinib in colorectal cancer patients in China, a potentially large market for its lead drug, and is pushing ahead with US development plans for the VEGFR inhibitor. The Hong Kong-based firm also sees attractive possibilities for combination use in earlier lines of therapy and in additional indications and mature markets, its CEO says.
Register for our free email digests: